argenx Delivers Strong First Half Performance! Aug 13 Written by Kimberly Hicks Kimberly Hicks Previous Previous Dewpoint Therapeutics Doses First Patient in Phase 1a/2a Trial of DPTX3186 Next Next Alnylam Pharmaceuticals continues to lead in RNAi therapeutics with a standout quarter!
